Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

被引：0

作者：

Oh, Do-Youn ^{[1
]}

Park, Joon Oh ^{[2
]}

Kindler, Hedy L. ^{[3
]}

Hammel, Pascal ^{[4
]}

Reni, Michele ^{[5
]}

Van Cutsem, Eric ^{[6
]}

Macarulla, Teresa ^{[7
]}

Hall, Michael J. ^{[8
]}

Arnold, Dirk ^{[9
]}

Reinacker-Schick, Anke ^{[10
]}

Tortora, Giampaolo ^{[11
]}

Algul, Hana ^{[12
]}

O'Reilly, Eileen M. ^{[13
]}

McGuiness, David ^{[14
]}

Liu, Yu-Zhen ^{[14
]}

Cui, Karen ^{[15
]}

Schlienger, Katia ^{[16
]}

Locker, Gershon Y. ^{[15
]}

Golan, Talia ^{[17
]}

机构：

[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Paris VII, Hop Beaujon Clichy, Paris, France

[5] IRCCS Osped San Raffaele Sci Inst, Milan, Italy

[6] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Leuven, Belgium

[7] Vall Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Asklepios Tumorzentrum Hamburg Asklepios Klin Al, Hamburg, Germany

[10] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[11] Fdn Policlin Gemelli IRCCS, Med Oncol Unit, Rome, Italy

[12] Tech Univ Munich, Klin Rechts Isar, Munich, Germany

[13] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Tel Aviv Univ, Sheba Med Ctr, Inst Oncol, Tel Aviv, Israel

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO31-6

引用

页码：S319 / S319

页数：1

共 50 条

[21] Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY
Tutt, Andrew N. J.
Garber, Judy E.
Geyer, Charles E., Jr.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1440 - 1440
[22] Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
Hammel, P.
Kindler, H. L.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Joo, S.
Yoo, H. K.
Patel, N.
Golan, T.
Chantrill, Lorraine
Goldstein, David
Joubert, Warren
Pavlakis, Nick
Tognela, Annette
Van Cutsem, Eric
Van Fraeyenhove, Frank
Van Laethem, Jean-Luc
Peeters, Marc
Dhani, Neesha
Kavan, Petr
Lemay, Frederic
Adenis, Antoine
Artru, Pascal
Hamed, Nabil
Belletier, Christine
Ben Abdelghani, Meher
Blanc, Jean-Frederic
Borg, Christophe
Coriat, Romain
Deplanque, Gael
Faroux, Roger
Follana, Philippe
Guimbaud, Rosine
el Hajbi, Farid
Hammel, Pascal
Hautefeuille, Vincent
Malka, David
Metges, Jean-Philippe
Tougeron, David
ANNALS OF ONCOLOGY, 2019, 30 (12) : 1959 - 1968
[23] The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
Wibisono, M. G.
Wibisono, M. H.
Sabran, M. Z.
Wibisono, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1404
[24] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Angela Cho
Jeong-Yeol Park
Shin-Wha Lee
Dae-Yeon Kim
Dae-Shik Suh
Jong-Hyeok Kim
Yong-Man Kim
Young-Tak Kim
Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
[25] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
Cho, Angela
Park, Jeong-Yeol
Lee, Shin-Wha
Kim, Dae-Yeon
Suh, Dae-Shik
Kim, Jong-Hyeok
Kim, Yong-Man
Kim, Young-Tak
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
[26] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, Mark
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine
Armstrong, Anne
Wu, Wenting
Goessl, Carsten
Runswick, Sarah
Conte, Pierfranco
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06): : 523 - 533
[27] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Domchek, Susan M.
Postel-Vinay, Sophie
Im, Seock-Ah
Park, Yeon Hee
Delord, Jean-Pierre
Italiano, Antoine
Alexandre, Jerome
You, Benoit
Bastian, Sara
Krebs, Matthew G.
Wang, Ding
Waqar, Saiama N.
Lanasa, Mark
Rhee, Joon
Gao, Haiyan
Rocher-Ros, Vidalba
Jones, Emma, V
Gulati, Sakshi
Coenen-Stass, Anna
Kozarewa, Iwanka
Lai, Zhongwu
Angell, Helen K.
Opincar, Laura
Herbolsheimer, Pia
Kaufman, Bella
LANCET ONCOLOGY, 2020, 21 (09): : 1155 - 1164
[28] Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial
Kindler, H.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M.
Park, J.
Hochhauser, D.
Arnold, D.
Oh, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
McGuinness, D.
Cui, K.
Schlienger, K.
Locker, G.
Golan, T.
ANNALS OF ONCOLOGY, 2020, 31 : S218 - S218
[29] Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
Lieberman, Howard B.
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 418 - 420
[30] Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
Mehra, Tarun
Lupatsch, Judith E.
Kossler, Thibaud
Dedes, Konstantin
Siebenhuner, Alexander Reinhard
von Moos, Roger
Wicki, Andreas
Schwenkglenks, Matthias E.
PLOS ONE, 2024, 19 (04):

← 1 2 3 4 5 →